TrialLancet (London, England)2019

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Ulrich Herrlinger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.